Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Minerva Outlines Next Steps For US Application For Schizophrenia Candidate

Published 07/04/2022, 17:49
Updated 07/04/2022, 18:42
© Reuters.  Minerva Outlines Next Steps For US Application For Schizophrenia Candidate

© Reuters. Minerva Outlines Next Steps For US Application For Schizophrenia Candidate

Minerva Neurosciences Inc (NASDAQ: NERV) received the official meeting minutes from the Type C meeting with the FDA regarding the development of roluperidone for negative symptoms in schizophrenia.

  • The agency cited concerns related to the applicability of the results of the Phase 2b study (conducted in Europe) to the US population.
  • The agency raised concern regarding the proposed use of post hoc analyses for the primary endpoint results of the Phase 3 study.
  • Even by excluding one trial site that Minerva believes to be subject to potential data integrity issues, the overall study remains negative.
  • For the Phase 3 study to be positive, both roluperidone doses must be statistically significant versus placebo, which was not the case for the 32 mg dose, the agency noted.
  • Related: Minerva Posts Positive Bioequivalence Results For Schizophrenia Candidate Formulations.
  • Excluding the trial site with data integrity issues resulted in a nominal p-value of 0.044 on the primary endpoint for the 64 mg dose. In the Phase 2b study, the 64 mg and the 32 mg doses of roluperidone achieved statistical significance versus placebo.
  • Minerva stated that the relapse rate in these trials was less than 15% of the treated population compared to over 25% in other trials in which patients were treated with antipsychotics.
  • The FDA advised that additional data collection could begin in parallel with Minerva's preparations for a potential marketing application.
  • Price Action: NERV shares are up 3.02% at $0.89 during the market session on the last check Thursday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read at Benzinga

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.